Shots:

• The P-III CANOPY-2 study involves assessing canakinumab (ACZ885) + CT (docetaxel) in 237 adults with LA/m-NSCLC- prior treatment with PD-L1 inhibitors and Pt-based CT. The study did not meet its 1EPs of OS
• The company will continue to evaluate the therapy in ongoing P-III CANOPY-1 and CANOPY-A studies evaluating canakinumab in 1L and adjuvant settings. The CANOPY-1 results are expected before the end of 2021
• Canakinumab is a mAb that binds with high affinity and selectivity to human IL-1β and acts by blocking its interaction with its receptor

 ­ Ref: GlobeNewswire | Image: Novartis